Characteristics of All Pseudomonas aeruginosa Posttraumatic Osteomyelitis Episodes Followed up, April 2018 to January 2022, Médecins Sans Frontières–Supported Facilities in Mosul (Iraq) and Gaza (Palestine)
| Characteristic per PAPTO Episode . | Total Episodes (n = 66) . | Mosul (n = 21) . | Gaza (n = 45) . | P Valuea . |
|---|---|---|---|---|
| Hospitalization and clinical characteristics | ||||
| Length of stay, d, median (IQR) | 42 (24–53) | 30 (21–48) | 43 (24–60) | .30 |
| Surgical interventions, median (IQR) | 2 (1–5) | 4 (1–6) | 1 (1–5) | .05 |
| Clinical signs of infection at admission | ||||
| Yes | 62 (93.9) | 21 (100.0) | 41 (91.1) | .30 |
| No | 4 (6.1) | 0 (0.0) | 4 (8.9) | |
| Months of follow-up during study period | ||||
| ≤6 mo | 28 (46.7) | 13 (68.4) | 15 (36.6) | .02 |
| >6 mo | 32 (53.3) | 6 (31.6) | 26 (63.4) | |
| Days completed under follow-up, median (IQR) | 203 (72–443) | 86 (24–213) | 294 (111–475) | .01 |
| Time from injury to first biopsy, d, median (IQR) | 357 (37–698) | 394 (20–1153) | 324 (45–635) | .27 |
| Biopsy-related characteristics | ||||
| Bone samples collected per episode, median (IQR) | 5 (4–5) | 4 (3–5) | 5 (4–5) | .01 |
| Time from sample collection to biopsy results, d, median (IQR) | 5 (4–7) | 4 (3–4) | 6 (4–8) | <.001 |
| Length of treatment, d, mean (SD) | 45.5 (15.6) | 39.4 (9.6) | 48.4 (17.1) | .032 |
| Infection-related characteristics | ||||
| Polymicrobial | ||||
| Yes | 49 (74.2) | 12 (57.1) | 37 (82.2) | .03 |
| No | 17 (25.8) | 9 (42.9) | 8 (17.8) | |
| Multidrug-resistant PTOb | ||||
| Yes | 43 (65.1) | 12 (57.1) | 31 (68.9) | .35 |
| No | 23 (34.8) | 9 (42.9) | 14 (31.1) | |
| Multidrug-resistant PAPTO | ||||
| Yes | 25 (37.9) | 4 (19.0) | 21 (46.7) | .06 |
| No | 41 (62.1) | 17 (81.0) | 24 (53.3) | |
| Characteristic per PAPTO Episode . | Total Episodes (n = 66) . | Mosul (n = 21) . | Gaza (n = 45) . | P Valuea . |
|---|---|---|---|---|
| Hospitalization and clinical characteristics | ||||
| Length of stay, d, median (IQR) | 42 (24–53) | 30 (21–48) | 43 (24–60) | .30 |
| Surgical interventions, median (IQR) | 2 (1–5) | 4 (1–6) | 1 (1–5) | .05 |
| Clinical signs of infection at admission | ||||
| Yes | 62 (93.9) | 21 (100.0) | 41 (91.1) | .30 |
| No | 4 (6.1) | 0 (0.0) | 4 (8.9) | |
| Months of follow-up during study period | ||||
| ≤6 mo | 28 (46.7) | 13 (68.4) | 15 (36.6) | .02 |
| >6 mo | 32 (53.3) | 6 (31.6) | 26 (63.4) | |
| Days completed under follow-up, median (IQR) | 203 (72–443) | 86 (24–213) | 294 (111–475) | .01 |
| Time from injury to first biopsy, d, median (IQR) | 357 (37–698) | 394 (20–1153) | 324 (45–635) | .27 |
| Biopsy-related characteristics | ||||
| Bone samples collected per episode, median (IQR) | 5 (4–5) | 4 (3–5) | 5 (4–5) | .01 |
| Time from sample collection to biopsy results, d, median (IQR) | 5 (4–7) | 4 (3–4) | 6 (4–8) | <.001 |
| Length of treatment, d, mean (SD) | 45.5 (15.6) | 39.4 (9.6) | 48.4 (17.1) | .032 |
| Infection-related characteristics | ||||
| Polymicrobial | ||||
| Yes | 49 (74.2) | 12 (57.1) | 37 (82.2) | .03 |
| No | 17 (25.8) | 9 (42.9) | 8 (17.8) | |
| Multidrug-resistant PTOb | ||||
| Yes | 43 (65.1) | 12 (57.1) | 31 (68.9) | .35 |
| No | 23 (34.8) | 9 (42.9) | 14 (31.1) | |
| Multidrug-resistant PAPTO | ||||
| Yes | 25 (37.9) | 4 (19.0) | 21 (46.7) | .06 |
| No | 41 (62.1) | 17 (81.0) | 24 (53.3) | |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IQR, interquartile range; PAPTO, posttraumatic osteomyelitis caused by Pseudomonas aeruginosa; PTO, posttraumatic osteomyelitis; SD, standard deviation.
aP < .05 is statistically significant.
bCalculated among recurrent infections including non-PAPTO (new infections isolated from PAPTO patients, caused by bacteria other than P aeruginosa).
Characteristics of All Pseudomonas aeruginosa Posttraumatic Osteomyelitis Episodes Followed up, April 2018 to January 2022, Médecins Sans Frontières–Supported Facilities in Mosul (Iraq) and Gaza (Palestine)
| Characteristic per PAPTO Episode . | Total Episodes (n = 66) . | Mosul (n = 21) . | Gaza (n = 45) . | P Valuea . |
|---|---|---|---|---|
| Hospitalization and clinical characteristics | ||||
| Length of stay, d, median (IQR) | 42 (24–53) | 30 (21–48) | 43 (24–60) | .30 |
| Surgical interventions, median (IQR) | 2 (1–5) | 4 (1–6) | 1 (1–5) | .05 |
| Clinical signs of infection at admission | ||||
| Yes | 62 (93.9) | 21 (100.0) | 41 (91.1) | .30 |
| No | 4 (6.1) | 0 (0.0) | 4 (8.9) | |
| Months of follow-up during study period | ||||
| ≤6 mo | 28 (46.7) | 13 (68.4) | 15 (36.6) | .02 |
| >6 mo | 32 (53.3) | 6 (31.6) | 26 (63.4) | |
| Days completed under follow-up, median (IQR) | 203 (72–443) | 86 (24–213) | 294 (111–475) | .01 |
| Time from injury to first biopsy, d, median (IQR) | 357 (37–698) | 394 (20–1153) | 324 (45–635) | .27 |
| Biopsy-related characteristics | ||||
| Bone samples collected per episode, median (IQR) | 5 (4–5) | 4 (3–5) | 5 (4–5) | .01 |
| Time from sample collection to biopsy results, d, median (IQR) | 5 (4–7) | 4 (3–4) | 6 (4–8) | <.001 |
| Length of treatment, d, mean (SD) | 45.5 (15.6) | 39.4 (9.6) | 48.4 (17.1) | .032 |
| Infection-related characteristics | ||||
| Polymicrobial | ||||
| Yes | 49 (74.2) | 12 (57.1) | 37 (82.2) | .03 |
| No | 17 (25.8) | 9 (42.9) | 8 (17.8) | |
| Multidrug-resistant PTOb | ||||
| Yes | 43 (65.1) | 12 (57.1) | 31 (68.9) | .35 |
| No | 23 (34.8) | 9 (42.9) | 14 (31.1) | |
| Multidrug-resistant PAPTO | ||||
| Yes | 25 (37.9) | 4 (19.0) | 21 (46.7) | .06 |
| No | 41 (62.1) | 17 (81.0) | 24 (53.3) | |
| Characteristic per PAPTO Episode . | Total Episodes (n = 66) . | Mosul (n = 21) . | Gaza (n = 45) . | P Valuea . |
|---|---|---|---|---|
| Hospitalization and clinical characteristics | ||||
| Length of stay, d, median (IQR) | 42 (24–53) | 30 (21–48) | 43 (24–60) | .30 |
| Surgical interventions, median (IQR) | 2 (1–5) | 4 (1–6) | 1 (1–5) | .05 |
| Clinical signs of infection at admission | ||||
| Yes | 62 (93.9) | 21 (100.0) | 41 (91.1) | .30 |
| No | 4 (6.1) | 0 (0.0) | 4 (8.9) | |
| Months of follow-up during study period | ||||
| ≤6 mo | 28 (46.7) | 13 (68.4) | 15 (36.6) | .02 |
| >6 mo | 32 (53.3) | 6 (31.6) | 26 (63.4) | |
| Days completed under follow-up, median (IQR) | 203 (72–443) | 86 (24–213) | 294 (111–475) | .01 |
| Time from injury to first biopsy, d, median (IQR) | 357 (37–698) | 394 (20–1153) | 324 (45–635) | .27 |
| Biopsy-related characteristics | ||||
| Bone samples collected per episode, median (IQR) | 5 (4–5) | 4 (3–5) | 5 (4–5) | .01 |
| Time from sample collection to biopsy results, d, median (IQR) | 5 (4–7) | 4 (3–4) | 6 (4–8) | <.001 |
| Length of treatment, d, mean (SD) | 45.5 (15.6) | 39.4 (9.6) | 48.4 (17.1) | .032 |
| Infection-related characteristics | ||||
| Polymicrobial | ||||
| Yes | 49 (74.2) | 12 (57.1) | 37 (82.2) | .03 |
| No | 17 (25.8) | 9 (42.9) | 8 (17.8) | |
| Multidrug-resistant PTOb | ||||
| Yes | 43 (65.1) | 12 (57.1) | 31 (68.9) | .35 |
| No | 23 (34.8) | 9 (42.9) | 14 (31.1) | |
| Multidrug-resistant PAPTO | ||||
| Yes | 25 (37.9) | 4 (19.0) | 21 (46.7) | .06 |
| No | 41 (62.1) | 17 (81.0) | 24 (53.3) | |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IQR, interquartile range; PAPTO, posttraumatic osteomyelitis caused by Pseudomonas aeruginosa; PTO, posttraumatic osteomyelitis; SD, standard deviation.
aP < .05 is statistically significant.
bCalculated among recurrent infections including non-PAPTO (new infections isolated from PAPTO patients, caused by bacteria other than P aeruginosa).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
